Overview

Combined CFRT and SABR in Stage II and III NSCLC With Peripheral Tumors Smaller Than 5 cm.

Status:
Completed
Trial end date:
2018-11-11
Target enrollment:
Participant gender:
Summary
A phase I trial is being conducted in patients with inoperable locally advanced NSCLC to treat with a combination of Conventional Fractionated Radiotherapy (CFRT) on the mediastinal lymph nodes and Stereotactic Ablative Radiotherapy (SABR)on the primary tumor with concurrent chemotherapy. It is hypothesized that this will lead to an increase of local control and overall survival
Phase:
Phase 1
Details
Lead Sponsor:
The Netherlands Cancer Institute
Treatments:
Cisplatin